This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.The purpose of this study is to investigate the safety and efficacy of rituximab in combination with mycophenolate mofetil (MMF) compared with placebo in combination with MMF in the treatment of lupus nephritis. Rituximab is a monoclonal antibody, which is a protein that helps protect the body against foreign materials. It decreases some types of B-cells in the body which may be important in inflammation. Rituximab has been used in a small number of patient with lupus nephritis, and this study is designed to further evaluate whether rituximab would reduce the signs and symptoms of lupus and lupus nephritis.
Showing the most recent 10 out of 589 publications